The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Prostate Cancer Case Studies

E. David Crawford, MD: Safety and Tolerability Issues

E. David Crawford, MD
Published Online:Jun 18, 2015
Bernie H. is a 75-year-old retired restaurant manager from Queens, New York, who now lives part time in Boca Raton, Florida. He and his wife enjoy boating and fishing.

Metastatic Prostate Cancer: Case 1

Bernie is reasonably healthy and should tolerate any of the regimens commonly used, including abiraterone, enzalutamide, and chemotherapy. Another option would be immunotherapy. All of these therapies should be well tolerated in Bernie.

CASE 1: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Bernie H. is a 75-year-old retired restaurant manager from Queens, New York, who now lives part time in Boca Raton, Florida. He and his wife enjoy boating and fishing.
  • His prior medical history is notable for mild COPD, which is well controlled with salbutamol, and for arthritis, with total knee replacement in 2007
  • In 2004, he presented to his PCP with symptoms of nocturia × 3. A suspicious digital rectal examination and elevated PSA of 9 mg/mL was noted
  • 12 core biopsies revealed prostate adenocarcinoma of Gleason grade 7 (4 + 3) in 6 of 12 cores on the right side; he was treated with brachytherapy and a short course of 4 months of ADT. Within 6 months, his PSA had declined to undetectable levels (<.02 ng/mL). No further PSA testing was performed until 2011
In December 2011, the patient’s PSA was noted to be 12 ng/mL.
  • Patient was asymptomatic at the time; however, a pelvic CT scan showed an enlarged right iliac lymph node measuring 2.3 cm × 2.2 cm; biopsy of the lesion was consistent with prostate adenocarcinoma
  • Bone scan at the time was negative
  • The patient was started on ADT with 3 months of depot leuprolide and bicalutamide, and his PSA reached a nadir of <.02 ng/mL; testosterone level was <10 ng/mL
  • The patient was asymptomatic, and PSA was monitored every 3 months. His PSA slowly rose from the nadir over the next 4 years in spite of ADT
  • His liver function tests were unremarkable
By March of 2015, the patient had experienced 2 consecutive rises in PSA, first to 16 ng/mL, and then to 27 ng/mL; his testosterone level was <20 ng/dL.
  • CT scan again detected enlargement of the prior iliac lymph node to 2.5 cm × 2.4 cm, and Bernie’s physician confirmed a diagnosis of mCRPC in 2 additional lymph nodes
  • The patient remains asymptomatic, and his oncologist has ascertained progression of his disease
  • A bone scan was not performed, because the patient wanted to return home as soon as possible
  • Bernie and his wife are driving back to New York in their RV in late April. He wants to keep his cancer in check, but is concerned about side effects disrupting their trip
Publications
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.